ASCO GI 2023 Conference Coverage
Playback speed
10 seconds
ASCO GI 2023 Survival Analysis of the Phase II Randomized DEEPER Trial by JACCRO: m-FOLFOXIRI + Cetuximab vs. m-FOLFOXIRI + Bevacizumab as Initial Treatment for Unresectable RAS & BRAF Wild-Type mCRC
By
ASCO GI 2023 Conference Coverage
FEATURING
Yu Sunakawa
By
ASCO GI 2023 Conference Coverage
FEATURING
Yu Sunakawa
300 views
January 20, 2023
Login to view comments.
Click here to Login
Videos